NCCN adds ArteraAI post-prostatectomy test to guideline for biochemical recurrence risk
News · Targeted Oncology · 2026-11-12. Number 2 in the UrologyWatch Top 5 for November 16, 2026.
NCCN guidelines now include the ArteraAI test, an AI-based prognostic tool, for risk assessment after radical prostatectomy in the setting of biochemical recurrence.
Why it matters: Signals growing guideline incorporation of AI-based prognostic biomarkers into routine post-prostatectomy decision-making.
Source: Targeted Oncology
Loading today's edition…